INTRODUCTION
To identify a drug that is safe, affordable and effective is a challenge to modern medicine today. Current estimates are that it may cost as much as over a billion dollar to develop a drug by a pharmaceutical company.
[1] Drug discovery strategies based on natural products and traditional medicine are reemerging as attractive options.
[2] A folk medicine or Ayurvedic drug which has already been in use for many years having anecdotal evidence of efficacy for the treatment of a disease (which is also presumed to be safe) can be tested for efficacy in a clinical trial. This method has been described as 'reverse pharmacology'. [3] The drugs commonly used to treat inflammation and arthritis include glucocorticoids like cortisone and prednisone, NSAIDS like Ibuprofen and naproxen etc., disease-modifying anti-inflammatory and anti-rheumatic drugs like Methotrexate (MTX) and leflunomide etc., and newer therapies such as biological response modifiers like tumor necrosis factor, alpha blocking agents, anti-CD 20 therapy (rituximab) and abatacept which are often required to inhibit or halt the underlying immune processes.
However, besides high costs, all of these drugs are associated with numerous side effects, severe adverse reactions and toxicity, including some risk of infections in subsets of patients who are being treated with biological response modifiers.
[4], [5] Leonotis nepetifolia (L. Manocha N et al, (2012) reported the anti-inflammatory and anti-rheumatic activities of methanolic extract of capitulum(flowering head) of LN.
[9] Stigmasterol and Leonotinin [10] isolated from the plant has shown significant antiinflammatory activity. Flavonoids present in the plant are also said to attribute anti-inflammatory effect.
An analysis of the tribal claims and previous pharmacological works indicates the potential of the plant to be an anti arthritic drug which needs to be validated through preclinical, safety and efficacy trials. Hence the present pharmacological study was designed to evaluate the efficacy of thedecoction (traditional dosage form) and dry aqueous extract (modified dosage form) of LN in suitable animal experimental models for its anti-arthritic activity.
MATERIALS AND METHODS

Animals
Wistar strain albino rats of either sex weighing between 170 to 250 g were used for the 
Preparation of Dosage form
For pharmacological evaluation, coarse powder of the test drug was used to prepare decoction as per classical method. One part of drug to 16 parts of water and reduced to quarter part. Aqueous extract of the whole plant was prepared with the total yield of 16.4%. Decoction was administered without diluting it, while for extract; stock solution of suitable concentration was prepared freshly with distilled water just prior to administration.
Dose Fixation
Dose of the drug was calculated by extrapolating the human therapeutic dose to rat on the basis of body surface area ratio (conversion factor 0.018 for rat) by referring to the table of Pagets and Barnes (1964).
[11]
Human dose of LN decoction is 50 ml per day as used by the tribals, hence the dose for rat was calculated as 4.5 ml/kg body weight of rat. Similarly the human dose of extract was fixed as 1000 mg/day based on which the dose for rat was decided as 90 mg/kg body weight of rat.
Route of administration
The test drugs suspension administered according to the body weight of the animals by oral route with the help of oral feeding canula.
Chemicals
Freund's complete adjuvant (FCA) was purchased from Sigma Aldrich (Product no. F5881). Dexamethasone IP (Batch No. LM 1399) obtained from Cadila Healthcare Limited, Ahmedabad. All chemicals or reagents used in the experimental study were procured from standard and reputed firms and were generally and whenever available are of analytical grade regularly used in the laboratory.
Evaluation of test drug effect on Freund's complete adjuvant induced arthritis in rats
The selected animals were grouped into five groups of 6 rats each. First group (normal control) was administered tap water. Second group (arthritic control) was administered tap water orally and injected with FCA. Third group (Dry aqueous extract) was administered with 90mg/kg body weight dry aqueous extract of LN orally (p.o.). Fourth group (Decoction) was treated with 4.5ml/kg body weight decoction of LN p.o. The fifth group (reference standard [RS]) was administered with the standard drug Dexamethasone (100 μg/kg). The test drugs and RS were administered for 30 consecutive days. On day 1, the complete FCA was made into fine emulsion with the help of a syringe and 0.1 ml of it was injected beneath the plantar aponeurosis in the left hind paw and 0.05 ml subcutaneously into the root of the tail. The volumes of both the hind paws were measured with the help of digital plethysmometer just before the adjuvant injection (initial). Paw volumes of both hind limbs were recorded on the day of adjuvant injection and again measured on 2nd, 5th, 10th, and 15th day, and 15th, 20th, 25th, and 30th day for primary and secondary oedema respectively. Paw volume of the 0 (initial) days were taken as the reference value for determining the increase in paw volume on the subsequent days. The animals were observed daily for the appearance of secondary lesion. On 30 th day after one hour of drug administration, animals were weighed again and anaesthetized by anaesthetic ether and blood was collected from retro orbital plexus by capillary puncturing and used for estimation of serum biochemical parameters. Parameters such as blood urea, [12] serum creatinine, [13] serum glutamate oxaloacetate transaminase, [14] serum glutamate pyruvate transaminase, [15] and serum alkaline phosphatase [16] were estimated by feeding requisite quantity of serum to the auto analyzer (Fully Automated Biochemical Random Access Analyzer, BS-200; Lilac Medicare Pvt. Ltd., Mumbai, Maharashtra, India) which was automatically drawn in to the instrument for estimating different parameters.
References given in the kit literature mentioning the basis of the methods on which test procedures was carried out. [17] Further both right and leftsynovial joints were dissected out and the histopathological slides were prepared by referring to standard procedure. The slides were viewed under trinocular research Carl-Zeiss's microscope at various magnifications to note down the changes in the microscopic features.
Statistical Analysis
The data generated during the study were analyzed by employing Student 't' test and one-way ANOVA followed by Dunnet's multiple 't' test for unpaired data to determine significant difference between groups at P<0.05. 
RESULTS
FCA induced rat paw oedema
Ponderal changes
Biochemical estimation
Out of all the biochemical parameters studied, significant increase was found in blood urea and nonsignificant increase in alkaline phosphatase level in Freund's arthritic control group in comparison to the normal control group. Serum creatinine was found decreased significantly in the decoction group in comparison to the arthritic control. All other parameters were found unaffected in drug and standard drugs treated groups in comparison to the control group and arthritic control group. (Table 4 ) 
Histopathological study
In Freund's adjuvant arthritis control rat remarkable degenerative changes in the form of bone and cartilage erosion and synovial membrane proliferation were observed in both the joints. These changes were found to be very much decreased in both the dosage of test drug and reference standard administered group (Plate 1a, 1b, 1c and1d).
Plate 1d
DISCUSSION
The Freund's adjuvant induced arthritis model in rats is frequently used to evaluate anti-arthritic activity of new drugs as it closely resembles clinical arthritis.
[18]
Therefore, this model is used with a relatively high degree of validity for evaluating agents with potential anti-arthritic activity. Four phases of arthritis are established by researchers on the basis of biochemical markers of arthritis viz., days 1-4 with acute local inflammation and systemic effects, days 7-12 with remission of acute inflammation and periarthritis, days 12-28 with chronic inflammation, periarthritis, and osteogenic activity and day 35 onward with permanent articular deformity and minimal inflammation. [19] This model has been used to study subchronic or chronic inflammation in rats and is of considerable relevance to understand patho-physiology and pharmacological control of inflammatory processes.
The determination of paw swelling is considered a simple, sensitive, and quick procedure for evaluating the degree of inflammation and assessing the therapeutic effects of drugs. In this study, rats were selected as an animal model sincethey develop a chronic swelling in multiple joints with an influence of inflammatory cells and followed by erosion of cartilage in joints and destruction of bones. Paw volumes of both hind limbs were recorded on the day of adjuvant injection and again measured on 2nd, 5th, 10th, and 15th day, and 15th, 20th, 25th and 30th day for primary and secondary oedema respectively. The 15 th day measurement is indicative of primary lesions and then onward measurement aids in estimating secondary lesions. On 21 st day, the secondary phase of rheumatoid arthritis becomes more evident and inflammatory changes spread systemically and become observable in the limb not injected with Freund's adjuvant. This is because of the manifestation of cell mediated immunity.
[20]
In the present study it was observed that LN extract form is having weak activity against primary oedema whereas LN decoction form did not show any effect on primary oedema. RS group showed significant decrease in primary oedema in rats on 10 th and 15 th day compared to FA control group. This indicates presence of weak anti-inflammatory activity in LN extract form and significant anti-inflammatory activity in reference standard. Among the serum biochemical parameters studied only one parameter was affected to significant extent by injection of Freund's adjuvant. Statistically significant increase in blood urea was observed in arthritic control group in comparison to normal control group. Increased blood urea level was reported in arthritic rats and it was hypothesized that substantial fraction of blood urea in arthritic rats comes from arginine synthesized in the kidney.
[21] The test formulations and RS did not have any significant influence on this parameter.
Body weight is considered as an indirect index of health status and recovery from disease. A change in body weight of rats is measured as one of the parameter to assess the course of the disease and the response to therapy of anti-inflammatory and anti-arthritic drugs. As the incidence and severity of arthritis is increased, a decrease in body weights of the rats occurs during the course of the experimental period and this observation is by the findings of previous study on alterations in the metabolic activities of diseased rats. [22] It has been suggested that, the decrease in body weight during inflammation is due to deficient absorption of nutrients through the intestine and that treatment with anti-inflammatory drugs normalizes the process of absorption. [23] In the present study, none of the groups showed weight gain except the normal control group. Arthritic control group showed marked decrease in body weight in comparison to initial values. Weight loss in the test drugs and standard groups were found to be lower in comparison to arthritic control group.
CONCLUSION
The overall assessment of pharmacological data revealed that folklore claim on the use of whole plant of L. nepetifolia in joint complaint is valid. Pharmacological studies suggest the beneficial effect of both dosage forms of L. nepetifolia against chronic inflammation and inhibition of periarthritis and osteogenic activity.
